RecruitingNCT07272616

Detection of Brain Metastases Using a Novel Gadolinium-Weighted MRI Sequence: A Prospective Comparison

A Prospective Comparative Study of a Novel Gadolinium-Weighted MRI Sequence Versus Conventional T1-Weighted Imaging for the Detection of Brain Metastases

Sponsor

Region Stockholm

Enrollment

100 participants

Start Date

Jan 28, 2026

Study Type

OBSERVATIONAL

Conditions

Brain Neoplasms

Summary

This study will evaluate a new type of MRI sequence designed to improve the visibility of brain metastases after gadolinium contrast injection. The purpose is to determine whether this novel "gadolinium-weighted" imaging method can detect more or smaller tumors than standard MRI techniques. Participants will undergo a routine brain MRI with contrast, followed by an additional scan using the new method. The goal is to improve diagnostic accuracy without increasing the contrast dose or scan time.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing a new type of MRI brain scan (using a novel gadolinium-weighted sequence) to standard MRI in detecting brain metastases — cancerous tumors that have spread to the brain from elsewhere in the body. The goal is to see if this new technique finds more or smaller tumors more clearly. **You may be eligible if...** - You are 18 or older - You are already scheduled for a brain MRI with contrast dye (gadolinium) for clinical reasons - You have known or suspected brain metastases from any primary cancer - You are able to lie still for the duration of the MRI **You may NOT be eligible if...** - You have a contraindication to MRI (e.g., certain metal implants or a pacemaker) - You have a known allergy or reaction to gadolinium contrast agents - Your kidney function is severely reduced (eGFR below 30) - You are unable to give informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTNovel Gadolinium-Weighted MRI Sequence

A post-contrast MRI sequence incorporating magnetization transfer (MT) preparation and flow-nulling with motion-sensitized driven equilibrium (MSDE). The sequence is optimized to suppress background tissue and vascular signal while enhancing the visibility of gadolinium-enhancing brain metastases. It is compared to conventional T1-weighted imaging in the same exam session.